<DOC>
	<DOC>NCT02628743</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety of olesoxime in participants with spinal muscular atrophy, focusing on the nature, frequency, and severity of adverse events, as well as effects on laboratory values, vital signs and ECG parameters.</brief_summary>
	<brief_title>A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy, Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Participation in the previous studies (TRO19622CLEQ11151 or TRO19622CLEQ12751) Able to comply with the study protocol, in the investigator's judgment, including ability to take study treatment and perform study visits For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 28 days after the last dose of olesoxime Female participants who are pregnant or lactating, or intending to become pregnant during the study Participants who, in the opinion of the investigator, are not suitable to participate in this openlabel study Participants who have developed study drug hypersensitivity to olesoxime or one of the formulation excipients, including sesame oil Concomitant or previous participation in any investigational drug or device study within 90 days prior to screening Concomitant or previous participation in a SMN2targeting antisense oligonucleotide study within 6 months prior to screening History of human immunodeficiency virus infection, history of Hepatitis B infection within the past year, history of Hepatitis C infection which has not been adequately treated History of illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study History or presence of an abnormal ECG that is clinically significant in the investigator's opinion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>